Graft Versus Host DiseasePhase 2NCT05808985
Intestinal Microbiome-based Research for the Prevention of Acute GVHD
A Phase 2 study testing sodium butyrate in people with Graft Versus Host Disease and Postbiotics, run by Soonchunhyang University Hospital at 1 site in South Korea.
Trial summary
Hematopoietic stem cell transplantation consists of preconditioning chemotherapy, stem cell infusion, and engraftment of hematopoietic stem cells. In this process, in the case of recipients who receive hematopoietic stem cells, their immune system is completely destroyed and then undergoes a situation in which it is… Read more about this study
- Who is it for?
- Ages 19 to 70 years
- Conditions the study is for
- Graft Versus Host Disease, Postbiotics, Butyrate
- What is being tested?
- sodium butyrate
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteSouth Korea
- Study dates
- 2 Sep 2022to 31 Dec 2023
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients undergoing hematopoietic stem cell transplantation
- Adult patients over 19 years and under 70 of age
Who cannot join
- Patients who did not agree to participate in the study
- If feces are not suitable for analysis
Trial locations and contacts
1 site in 1 country.
South Korea1 site, 1 recruiting
- Recruiting
Soonchunhyang University Seoul Hospital
Seoul, 04401
Seug Yun Yoon, MD, +82 010-9267-2281, ysy6496@schmc.ac.kr
About this study
Official title: Intestinal Microbiome-based Research for the Prevention of Acute Graft-versus-host Disease
Hematopoietic stem cell transplantation consists of preconditioning chemotherapy, stem cell infusion, and engraftment of hematopoietic stem cells. In this process, in the case of recipients who receive hematopoietic stem cells, their immune system is completely destroyed and then undergoes a situation in which it is reconstituted. In this process, the diversity of the intestinal microbiome is reduced, and it is widely known that a severe decrease is associated with the occurrence of an acute graft-versus-host reaction. Attempts to improve the intestinal microbiome include prebiotics, probiotics, and postbiotics. Prebiotics can be expected to improve the intestinal microbiome by acting as nutrients for beneficial bacteria in the intestine, but their role may be limited in situations where the diversity of the intestinal microbiome has already decreased. Probiotics are a method to expect improvement of the intestinal microbiome by administering the beneficial bacteria themselves in the intestine, but there is a difficulty in reaching the intestine properly through stomach acid, and there is a risk of causing sepsis in immunocompromised patients. Postbiotics is a product that beneficial bacteria metabolize and release prebiotics in the intestine, and the microbiome in the intestine is actually responsible for the function that affects the human body. Therefore, in this study, postbiotics are administered to patients undergoing hematopoietic stem cell transplantation who are concerned that the diversity of the intestinal microbiome may have already decreased, to improve the intestinal microbiome and hope to prevent graft-versus-host reactions through this. Furthermore, it is intended to improve the outcome of allogeneic hematopoietic stem cell transplantation.
Read the detailed description
- step After explaining the background and purpose of the study to the subjects undergoing hematopoietic stem cell transplantation at Soonchunhyang University Seoul Hospital and obtaining consent, before transplantation (D-7), on the day of transplantation (D0), and at the time of engraftment after transplantation (D+ 14), 30 days after transplantation (D+30), 3 months after transplantation (D+90), if complications occur after a total of 5 times, if the researcher deems it necessary, with the consent of the patient, additional feces are collected. About 10g per dose will be received and stored in a freezer at the Institute of Clinical Molecular Biology, Soonchunhyang University until December 2027, and DNA will be extracted and microbiome analyzed later, and discarded at the end of the study. In the process of allogeneic hematopoietic stem cell transplantation, the subjects had difficulty in oral intake during the transplantation process after pretreatment chemotherapy, so at the time of engraftment oral intake was possible, starting to take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭) for 3 months after transplantation Continue taking until All expenses incurred in the course of testing are borne by the researcher. The patient's clinical progress and test results related to hematopoietic stem cell transplantation are investigated based on medical records.
- Duration of subject participation and expected number of subjects For patients undergoing hematopoietic stem cell transplantation at our hospital from the date of IRB approval to December 2023 (About 20 patients a year receive hematopoietic stem cell transplantation at our center, and it is expected that about 30 patients will participate)
- Clinical Study Restrictions and Subject Obligations Subjects who agreed to the study must take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭) from the time of engraftment to 3 months after transplantation, and must collect and submit feces at the designated time and in an appropriate way.
- Conditions
- Graft Versus Host Disease, Postbiotics, Butyrate
- Being tested
- sodium butyrate
- Keywords
- butyrate, Graft Versus Host Disease, postbiotics
- Medical subject headings
- Graft vs Host Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
sodium butyrateDrug
Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭, per day)
| Study group | Role | What they receive |
|---|---|---|
| Butyrate | Experimental | Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭ per day) Receives: Drug: sodium butyrate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of GVHD
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Apr 2023
- Study start2 Sep 2022
- Primary completion30 Sep 2023 (estimated)
- Study completion31 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Graft Versus Host DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭)
- Masking
- None (open label)
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Soonchunhyang University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Seug yun Yoon, MD, Soonchunhyang University Hospital
- Investigators
- Jong-Ho Won, MD, PhD, Study chair, Soonchunhyang University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05808985
- Sponsor's protocol ID
- 2022-06-011
- Status last verified
- Jan 2023
- First submitted
- 27 Jan 2023
- Last updated
- 12 Apr 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intestinal Microbiome-based Research for the Prevention of Acute Graft-versus-host Disease
- ClinicalTrials.gov ID
- NCT05808985
- Acronym / sponsor ID
- 2022-06-011
- Conditions
- Graft Versus Host Disease, Postbiotics, Butyrate
- Keywords
- butyrate, Graft Versus Host Disease, postbiotics
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Soonchunhyang University HospitalUniversity, hospital or other
- Study start
- 2 Sep 2022 (actual)
- Primary completion
- 30 Sep 2023 (estimated)
- Study completion
- 31 Dec 2023 (estimated)
- First posted
- 12 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hematopoietic stem cell transplantation consists of preconditioning chemotherapy, stem cell infusion, and engraftment of hematopoietic stem cells. In this process, in the case of recipients who receive hematopoietic stem cells, their immune system is completely destroyed and then undergoes a situation in which it is reconstituted. In this process, the diversity of the intestinal microbiome is reduced, and it is widely known that a severe decrease is associated with the occurrence of an acute graft-versus-host reaction. Attempts to improve the intestinal microbiome include prebiotics, probiotics, and postbiotics. Prebiotics can be expected to improve the intestinal microbiome by acting as nutrients for beneficial bacteria in the intestine, but their role may be limited in situations where the diversity of the intestinal microbiome has already decreased. Probiotics are a method to expect improvement of the intestinal microbiome by administering the beneficial bacteria themselves in the intestine, but there is a difficulty in reaching the intestine properly through stomach acid, and there is a risk of causing sepsis in immunocompromised patients. Postbiotics is a product that beneficial bacteria metabolize and release prebiotics in the intestine, and the microbiome in the intestine is actually responsible for the function that affects the human body. Therefore, in this study, postbiotics are administered to patients undergoing hematopoietic stem cell transplantation who are concerned that the diversity of the intestinal microbiome may have already decreased, to improve the intestinal microbiome and hope to prevent graft-versus-host reactions through this. Furthermore, it is intended to improve the outcome of allogeneic hematopoietic stem cell transplantation.
Detailed description
- step After explaining the background and purpose of the study to the subjects undergoing hematopoietic stem cell transplantation at Soonchunhyang University Seoul Hospital and obtaining consent, before transplantation (D-7), on the day of transplantation (D0), and at the time of engraftment after transplantation (D+ 14), 30 days after transplantation (D+30), 3 months after transplantation (D+90), if complications occur after a total of 5 times, if the researcher deems it necessary, with the consent of the patient, additional feces are collected. About 10g per dose will be received and stored in a freezer at the Institute of Clinical Molecular Biology, Soonchunhyang University until December 2027, and DNA will be extracted and microbiome analyzed later, and discarded at the end of the study. In the process of allogeneic hematopoietic stem cell transplantation, the subjects had difficulty in oral intake during the transplantation process after pretreatment chemotherapy, so at the time of engraftment oral intake was possible, starting to take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭) for 3 months after transplantation Continue taking until All expenses incurred in the course of testing are borne by the researcher. The patient's clinical progress and test results related to hematopoietic stem cell transplantation are investigated based on medical records.
- Duration of subject participation and expected number of subjects For patients undergoing hematopoietic stem cell transplantation at our hospital from the date of IRB approval to December 2023 (About 20 patients a year receive hematopoietic stem cell transplantation at our center, and it is expected that about 30 patients will participate)
- Clinical Study Restrictions and Subject Obligations Subjects who agreed to the study must take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭) from the time of engraftment to 3 months after transplantation, and must collect and submit feces at the designated time and in an appropriate way.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭)
| Arm | Type | Receives |
|---|---|---|
| Butyrate | Experimental | Drug: sodium butyrateTake butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭ per day) |
Who may qualify
- Ages
- 19 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Patients undergoing hematopoietic stem cell transplantation
- Adult patients over 19 years and under 70 of age
Key exclusion criteria (2 listed)
- Patients who did not agree to participate in the study
- If feces are not suitable for analysis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| sodium butyrateTake butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭, per day) | Drug | Butyrate |
Primary outcome
Incidence of GVHD
Time frame: through study completion, an average of 1 year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Apr 2023.
- Individual participant dataSharing planned: No
Related trials for Graft Versus Host Disease
Active, not recruitingPhase 2
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
Graft-versus-host Disease
RecruitingEarly Phase 1
HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
Hematologic Malignancy
RecruitingObservational study
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Graft-Versus-Host Disease, Graft-versus-leukemia
RecruitingPhase 1/2
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
RecruitingPhase 1/2
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Graft vs Host Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jong-Ho Won, MD, PhD study chair
Soonchunhyang University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing sodium butyrate in people with Graft Versus Host Disease and Postbiotics, run by Soonchunhyang University Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 12 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Seug Yun Yoon, MD (+82 010-9267-2281, ysy6496@schmc.ac.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of GVHD (time frame: through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Apr 2023.